Soligenix Inc. (SNGX)
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçets Disease
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçets Disease
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General